Italia markets close in 2 hours 24 minutes

Inventiva S.A. (0RNK.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
4,2700-0,0550 (-1,27%)
Al 04:45PM GMT. Mercato aperto.
Schermo intero
Chiusura precedente4,3250
Aperto0,0000
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume3.417
Media VolumeN/D
Capitalizzazione811.786
Beta (5 anni mensile)1,11
Rapporto PE (ttm)N/D
EPS (ttm)-1,2670
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US

    New patent granted in the United States by the USPTO covers the use of lanifibranor for the potential treatment of cirrhotic patients at risk of progressing from compensated stage to decompensated stage This patent strengthens and expands the intellectual property protection of lanifibranor in the United States particularly for use for patients with cirrhotic NASH Daix (France), Long Island City (New York, United States), November 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Compa

  • GlobeNewswire

    Inventiva announces a new Director of the Board of Directors

    Daix (France), Long Island City (New York, United States), November 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announces that, effective on November 9th, 2022, Inventiva’s board of directors coopted Dr. Lucy Lu as the Director of its Board of Directors in lieu of S

  • GlobeNewswire

    Inventiva reports 2022 Third Quarter Financial Information¹

    Cash position2 at €72.6m as of September 30, 2022, not including the $12.6 million upfront payment received from Sino Biopharm on November 4, 2022Revenues of €0.1m for the first nine months of 2022 Daix (France), Long Island City (New York, United States), November 10, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepat